• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].

作者信息

Schädlich P K, Koltermann K C, Dippel F-W, Hagenmeyer E-G, Häussler B

机构信息

IGES Institut GmbH, Berlin.

出版信息

MMW Fortschr Med. 2010 Oct 14;152 Suppl 3:89-95.

PMID:21595152
Abstract
摘要

相似文献

1
[BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].甘精胰岛素治疗的基础胰岛素治疗（BOT）与地特胰岛素治疗的基础胰岛素治疗对比：基于德国法定医疗保险视角下甘精胰岛素（来得时）与地特胰岛素（诺和平）达标治疗（L2T3）研究结果的2型糖尿病治疗成本比较
MMW Fortschr Med. 2010 Oct 14;152 Suppl 3:89-95.
2
Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.基于LAPTOP试验的甘精胰岛素治疗2型糖尿病的经济学评价
Eur J Health Econ. 2008 May;9(2):165-70. doi: 10.1007/s10198-007-0057-2. Epub 2007 May 26.
3
Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.在德国现实条件下，使用甘精胰岛素或传统基础胰岛素治疗的2型糖尿病患者的资源利用和成本：LIVE-SPP研究
J Med Econ. 2008;11(4):695-712. doi: 10.3111/13696990802645726.
4
[Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].[2型糖尿病患者的降糖药物及耗材成本与治疗满意度。医疗保健研究LIVE-DE（德国甘精胰岛素与中性鱼精蛋白锌胰岛素对比）研究结果]
Dtsch Med Wochenschr. 2009 Jun;134(23):1207-13. doi: 10.1055/s-0029-1222595. Epub 2009 May 26.
5
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.德国基础支持口服疗法（BOT）中使用甘精胰岛素或地特胰岛素治疗2型糖尿病的一年成本比较。
Int J Clin Pharmacol Ther. 2010 Feb;48(2):129-37. doi: 10.5414/cpp48129.
6
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.评估艾塞那肽与甘精胰岛素治疗 2 型糖尿病的效果：德国环境下的成本效益分析。
Diabetes Obes Metab. 2009 Nov;11(11):1068-79. doi: 10.1111/j.1463-1326.2009.01099.x. Epub 2009 Sep 3.
7
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.德国2型糖尿病患者在基础-餐时胰岛素治疗方案中使用甘精胰岛素与地特胰岛素加餐时门冬胰岛素的成本比较
Ger Med Sci. 2010 Aug 5;8:Doc17. doi: 10.3205/000106.
8
[Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].[门诊接受基础-餐时（ICT）胰岛素治疗方案的2型糖尿病患者的糖尿病护理成本及治疗满意度：LIVE-COM研究结果]
Med Klin (Munich). 2010 Nov;105(11):792-801. doi: 10.1007/s00063-010-1136-1. Epub 2010 Dec 7.
9
Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.医疗补助计划覆盖的2型糖尿病患者开始胰岛素笔治疗后的医疗费用及药物依从性：一项回顾性数据库分析
Clin Ther. 2007 Jun;29(6 Pt 1):1294-305. doi: 10.1016/j.clinthera.2007.07.007.
10
[Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].[糖尿病患者高血糖治疗的成本。年龄、治疗类型及并发症的影响：德国CoDiM研究结果]
Med Klin (Munich). 2006 May 15;101(5):384-93. doi: 10.1007/s00063-006-1050-8.